stockmarketproxy
/
INSMNasdaq SEC EDGAR

INSMED Inc

Pharmaceutical Preparations·BRIDGEWATER, NJ·FY end 12/31·CIK 1104506
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$606.4M$363.7M$305.2M$245.4M$188.5M
Gross Profit——————
Operating Income-$1.2B-$878.3M-$709.6M-$457.3M-$375.1M
Net Income-$1.3B-$913.8M-$749.6M-$481.5M-$434.7M
Operating CF-$935.0M-$683.9M-$536.2M-$400.4M-$363.3M
Capex$32.6M$21.9M$13.3M$9.9M$7.3M
Free Cash Flow-$967.6M-$705.8M-$549.5M-$410.3M-$370.6M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-205.6%-241.5%-232.5%-186.4%-199.0%
Net Margin-210.5%-251.2%-245.6%-196.3%-230.6%
FCF Margin-159.6%-194.1%-180.1%-167.2%-196.6%
R&D / Revenue127.2%164.5%187.1%162.0%144.7%
Effective Tax-0.4%-0.4%-0.3%-0.3%0.4%
Debt / Equity1.477.80-7.0325.923.33
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
INSM
—
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
INSM
$10M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
INSM
-210.5%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%